Beta Drugs Ltd
Healthcare | Small Cap
Beta Drugs Ltd. shows a picture of strong financial health, marked by exceptional profitability and impressive growth. The company has a very stable foundation with very little reliance on debt. It is successfully expanding its sales and profits, indicating high demand for its services in the healthcare sector. However, a key area of concern is its operational efficiency. The company takes a long time to convert its inventory into sales and is particularly slow in collecting payments from its customers. This can tie up cash that could be used elsewhere. The future outlook points towards continued expansion, but its success will also depend on how it manages its day-to-day operations.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio6.80
- Profitability Ratio10.00
- Efficiency Ratio3.67
- Coverage Ratio6.80
- Solvency Ratio9.00
- Liquidity Ratio8.38
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentWeak
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Beta Drugs Ltd. shows a picture of strong financial health, marked by exceptional profitability and impressive growth. The company has a very stable foundation with very little reliance on debt. It is successfully expanding its sales and profits, indicating high demand for its services in the healthcare sector. However, a key area of concern is its operational efficiency. The company takes a long time to convert its inventory into sales and is particularly slow in collecting payments from its customers. This can tie up cash that could be used elsewhere. The future outlook points towards continued expansion, but its success will also depend on how it manages its day-to-day operations.
Overall Valuation Score
P/E RATIO (TTM)
110.66
Industry Median
36.13
Small Cap Median
35.79
P/E RATIO
40.27
P/B RATIO
8.68
Industry Median
6.08
Small Cap Median
6.08
P/S RATIO
7908.46
Industry Median
5.75
Small Cap Median
5.17
Others
PEG RATIO
1.09
EV/EBITDA RATIO
21.93
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company is experiencing an exceptional period of growth across all key areas. It is successfully increasing its revenues, profits, and asset base at a very impressive rate. This demonstrates strong market demand, effective business strategy, and a solid foundation for future expansion. This robust growth is a primary strength, indicating the company is performing very well in its market and is on a strong upward trajectory.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 58.62 | 23.37 | 30.4 | 22.3 | 6.35 |
| Operating Profit Growth Rate | 72 | 23.26 | 13.21 | 25 | 1.33 |
| Earnings Per Share (EPS) Growth | 111.9 | 23.76 | 18.61 | 16.46 | -2.62 |
| Asset Growth Rate | 33.9 | 25.32 | 28.28 | 71.65 | 13.76 |
| Net Income Growth Rate | 108.33 | 24 | 16.13 | 16.67 | -2.38 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
From a shareholder's perspective, the company's financial metrics are strong, with high and growing earnings and book value per share. This indicates the underlying value of the company is increasing. However, the company is not providing a direct return to shareholders through dividends, as it is reinvesting all its profits. It is also spending significantly on capital expenditures to fuel its expansion, which is a long-term investment.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 25 | 31 | 36 | 45.37 | 41 |
| Cash Earnings Per Share (Cash EPS) | 32 | 41 | 46 | 55 | 58 |
| Book Value Per Share | 93 | 123 | 158 | 197 | 245 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 19.4 | 18.2 | 11.6 | 36.9 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's ability to generate profit is excellent across all measures. It is highly effective at converting revenue into profit at the gross, operating, and net levels. Furthermore, it delivers very strong returns on the assets it owns, the capital it employs, and the equity invested by its shareholders. This all-around profitability is a major strength and indicates a highly efficient and successful business model.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.57 | 18.94 | 16.89 | 17.13 | 15.32 |
| Return on Capital Employed (ROCE) | 36 | 34 | 33 | 27 | 19 |
| Return on Equity (ROE) | 26.88 | 25.2 | 22.78 | 21.32 | 16.73 |
| Return on Assets (ROA) | 27.22 | 26.77 | 23.62 | 17.2 | 15.32 |
| Operating Margin | 23.37 | 23.35 | 20.27 | 20.72 | 19.74 |
| Net Margin | 13.59 | 13.66 | 12.16 | 11.6 | 10.65 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
This is the company's most significant area of challenge. While financially stable, its day-to-day operations show signs of inefficiency. The company is slow in selling its products and is particularly slow in collecting payments from its customers. This means a lot of its capital is tied up in inventory and unpaid bills. Furthermore, it is not generating as much revenue as it could from its assets and overall capital investments, which could limit its full growth potential.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.35 | 3.6 | 4.55 | 4.07 | 3.08 |
| Inventory Turnover Ratio | 7.79 | 6.94 | 6.07 | 5.47 | 4.87 |
| Receivables Turnover Ratio | 4.66 | 4.2 | 4.17 | 3.98 | 3.47 |
| Days Sales in Inventory Ratio | 46.85 | 52.59 | 60.13 | 66.73 | 74.95 |
| Receivable Days | 78.33 | 86.9 | 87.53 | 91.71 | 105.19 |
| Capital Turnover Ratio | 1.69 | 1.69 | 1.76 | 1.1 | 1.02 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's financial position allows it to comfortably cover its interest payments on debt, which is a strong positive sign of financial health. This reduces the risk associated with its borrowings. On the other hand, the company currently does not pay dividends to its shareholders. This suggests a strategy of retaining all earnings to fuel its significant growth and expansion plans, rather than distributing profits.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 18 | 21.5 | 17.33 | 9.14 | 4.6 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's long-term financial stability is excellent. It has a very low-risk profile because it finances its operations primarily through owner's funds rather than borrowing. This minimal reliance on debt means the company is well-insulated from financial risks related to interest rate changes and has a strong capacity to take on new debt for future growth if needed. Overall, its balance sheet is exceptionally strong and stable.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.15 | 0.08 | 0.06 | 0.4 | 0.35 |
| Debt to Equity Ratio | 0.18 | 0.09 | 0.06 | 0.67 | 0.54 |
| Equity Ratio | 0.85 | 0.92 | 0.94 | 0.6 | 0.65 |
| Debt To Asset Ratio | 0.1 | 0.06 | 0.04 | 0.3 | 0.27 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's ability to cover its short-term financial obligations is very strong. It holds a healthy amount of current assets, including cash, relative to its immediate liabilities, which reduces the risk of short-term cash flow problems. A positive aspect is its capacity to pay bills even without selling inventory. A potential concern is that the cash generated directly from its core business operations is comparatively low, suggesting it may rely on other financial activities to maintain its cash position.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.04 | 2.11 | 2.18 | 3.24 | 3.17 |
| Quick Ratio | 1.6 | 1.62 | 1.61 | 2.68 | 2.54 |
| Cash Ratio | 0.34 | 0.3 | 0.33 | 1.37 | 1.07 |
| Operating Cash Flow Ratio | 0.6 | 0.36 | 0.36 | 0.34 | 0 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Beta Drugs Ltd | 7.51 | 40.27 | Neutral | 76.00 | 13.76 | 41.00 |
| 5 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 6 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 7 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 8 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 9 | Tarsons Products Ltd | 5.90 | 97.63 | Neutral | 118.00 | 4.26 | 14.00 |
| 10 | Shalby Ltd | 5.85 | 49.37 | Undervalued | 143.00 | 10.45 | 35.00 |
Management demonstrates mixed effectiveness. Strengths are rooted in a strong historical growth track record, stable operating margins, and a robust shareholding structure with high promoter conviction and increasing institutional interest. However, significant concerns arise from recent and forward-looking data. Key weaknesses include a sharp deceleration in sales and profit growth, with TTM profit growth turning negative. Capital efficiency is deteriorating, as evidenced by declining ROCE and a worsening cash conversion cycle. The most critical issue is a projected massive increase in debt, which significantly alters the company's previously conservative financial profile. The combination of past strengths with current and future weaknesses warrants a cautious, mixed assessment.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Strong Promoter Holding | 64.63% | strong |
| Increasing Institutional Holding | FII: 1.16%, DII: 2.15% | improving | |
| Stable Operating Profit Margins | ~20% | stable | |
| Strong 5Y Compounded Sales Growth | 27% | strong | |
| CONS | Declining TTM Profit Growth | -9% | weak |
| Projected Surge in Borrowings | ₹15 Cr to ₹148 Cr | poor | |
| Deteriorating Return on Capital | ROCE from 36% to 19% | declining | |
| Worsening Cash Conversion Cycle | 100 Days | weak |
Financial Performance & Growth
The company's financial performance shows a clear deceleration. While historical growth was robust, with a 5-year compounded sales growth of 27%, recent trends are concerning. TTM sales growth has slowed to 6%, and TTM profit growth is negative at -9%. Quarterly results confirm this weakness, with year-over-year sales growth at a marginal 0.21% and profit declining by -15.18% in the latest quarter (Mar 2026). Operating profit margins (OPM) have remained relatively stable around 20%, indicating consistent operational management. However, this has not translated to the bottom line, as net profit growth has turned negative. The volatility in quarterly net profits further underscores the inconsistency in recent earnings performance.
| Metric (Compounded Growth %) | 10 Years | 5 Years | 3 Years | TTM |
|---|---|---|---|---|
| Sales Growth | - | 27% | 19% | 6% |
| Profit Growth | - | 29% | 11% | -9% |
Capital Efficiency & Returns
Capital efficiency and shareholder returns are on a declining trend. Return on Capital Employed (ROCE) has fallen from a peak of 36% in FY22 to a projected 19% in FY26. Similarly, Return on Equity (ROE) is projected to decline from 22.8% in FY24 to 16.7% in FY26. This indicates that the capital and shareholder funds are generating lower returns over time. The weakening efficiency is also visible in working capital management. The Cash Conversion Cycle (CCC) has elongated from 53 days in FY22 to a projected 100 days in FY26, suggesting that more cash is being tied up in operations. Furthermore, the Asset Turnover ratio is projected to decline from 1.16 in FY24 to 0.77 in FY26, showing that assets are becoming less effective at generating revenue.
| Metric | 2022 | 2023 | 2024 | 2025 (e) | 2026 (e) |
|---|---|---|---|---|---|
| ROCE (%) | 36% | 34% | 33% | 27% | 19% |
| ROE (%) | 26.7% | 25.2% | 22.8% | 21.3% | 16.7% |
| Cash Conversion Cycle (Days) | 53 | 68 | 75 | 79 | 100 |
Financial Health & Prudence
The company's financial health is set to deteriorate significantly due to a projected surge in debt. Historically, the company maintained low leverage, with a Debt-to-Equity ratio of just 0.09 in March 2024. However, borrowings are projected to increase nearly tenfold, from ₹15 Cr in FY24 to ₹148 Cr in FY26. This will raise the Debt-to-Equity ratio to 0.60 by FY26. This increased leverage severely impacts the Interest Coverage Ratio, which is expected to plummet from a comfortable 20x in FY24 to just 5.1x in FY26, indicating a reduced capacity to service debt obligations. The company has consistently maintained a zero dividend payout policy, retaining all earnings for reinvestment.
| Metric | 2022 | 2023 | 2024 | 2025 (e) | 2026 (e) |
|---|---|---|---|---|---|
| Borrowings (₹ Cr) | 21 | 20 | 15 | 138 | 148 |
| Debt/Equity Ratio | 0.23 | 0.16 | 0.09 | 0.70 | 0.60 |
| Interest Coverage Ratio (x) | 21.5 | 26.5 | 20.0 | 10.7 | 5.1 |
Shareholding & Ownership Structure
The shareholding structure is a key strength. Promoter holding is high and has remained stable, projected at 64.63% as of March 2026. This indicates strong alignment of interests between management and shareholders. Furthermore, there is a clear trend of increasing institutional investment. Foreign Institutional Investor (FII) holding has risen from being negligible in March 2022 to a projected 1.16% by March 2026. Domestic Institutional Investor (DII) holding shows an even more pronounced increase, growing from 0.29% to 2.15% over the same period. This growing interest from FIIs and DIIs suggests increasing confidence from sophisticated investors in the company's long-term prospects, despite recent operational headwinds.
| Shareholding (%) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 (e) | Mar 2026 (e) |
|---|---|---|---|---|---|
| Promoters | 66.71% | 66.73% | 66.73% | 66.73% | 64.63% |
| FIIs | 0.00% | 0.29% | 0.32% | 0.90% | 1.16% |
| DIIs | 0.29% | 0.04% | 0.06% | 0.17% | 2.15% |
The overall risk profile is high due to a convergence of significant financial and operational risks. The most prominent risk is the sharp, projected increase in financial leverage. A nearly tenfold rise in borrowings significantly increases the company's vulnerability to economic downturns and interest rate hikes, as reflected in the rapidly declining interest coverage ratio. This financial strain is compounded by deteriorating operational performance, including a marked slowdown in growth, negative profit trends, and weakening working capital efficiency. The combination of taking on substantial debt while core business performance is faltering creates a high-risk scenario. The strong shareholding pattern provides some stability but does not mitigate the immediate and substantial financial and operational risks.
Accounting quality red flags
Several red flags emerge from the financial data. The most significant is the planned surge in borrowings from ₹15 Cr in FY24 to ₹148 Cr by FY26, which represents a major shift in financial policy and introduces substantial leverage risk. Another concern is the projected spike in 'Other Income' to ₹11 Cr in FY26, a stark deviation from the historical average of below ₹2 Cr. This income is expected to contribute approximately 20% of the Profit Before Tax, potentially masking weaker performance from core operations. Additionally, the Cash Flow from Operations to Operating Profit ratio has been inconsistent, fluctuating between 44% and 75% in recent years, indicating variability in earnings quality.
Foreign exchange or interest rate exposure
The company's exposure to interest rate risk is set to increase dramatically. With borrowings projected to rise from ₹15 Cr to ₹148 Cr, the company becomes highly sensitive to changes in interest rates. This is evident in the projected interest expense, which is expected to quintuple from ₹3 Cr in FY24 to ₹15 Cr in FY26. Such a substantial increase in fixed financial costs reduces the company's earnings buffer and financial flexibility. A rise in market interest rates could further compress profitability and strain the company's ability to service its debt, posing a significant financial risk.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe